Literature DB >> 3042625

Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience.

A Coune1.   

Abstract

Liposomes are microscopic, closed lipid vesicles able to entrap hydrophilic as well as lipophilic compounds. They constitute a versatile drug delivery system. When injected by the intravenous route, liposomes are taken up by macrophages in the liver and in the spleen. Investigation of several animal models of infections has shown that liposome-entrapped anti-infectious drugs are active against infections due to facultative intracellular bacteria, parasites such as Leishmania, viruses such as the one causing Rift valley fever. Liposomes of different lipid compositions, structures and sizes were used for intravenous administration of anti-infectious drugs without inducing toxicity in the tested animals. Clinical experience was obtained with two different liposomal preparations of amphotericin B in the treatment of systemic fungal diseases in cancer patients; these preparations were shown to be effective and very well-tolerated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042625     DOI: 10.1007/BF01644088

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  35 in total

1.  Antileishmanial activity of antimonials entrapped in liposomes.

Authors:  R R New; M L Chance; S C Thomas; W Peters
Journal:  Nature       Date:  1978-03-02       Impact factor: 49.962

2.  The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasis.

Authors:  C D Black; G J Watson; R J Ward
Journal:  Trans R Soc Trop Med Hyg       Date:  1977       Impact factor: 2.184

3.  Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  C Tremblay; M Barza; C Fiore; F Szoka
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  Protective effect of liposomal-amphotericin B against C. albicans infection in mice.

Authors:  G Lopez-Berestein; T McQueen; K Mehta
Journal:  Cancer Drug Deliv       Date:  1985

5.  Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.

Authors:  S G Reed; M Barral-Netto; J A Inverso
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

6.  Treatment of experimental murine candidiasis with liposome-associated amphotericin B.

Authors:  J Ahrens; J R Graybill; P C Craven; R L Taylor
Journal:  Sabouraudia       Date:  1984

7.  Amphotericin B in liposomes: a novel therapy for histoplasmosis.

Authors:  R L Taylor; D M Williams; P C Craven; J R Graybill; D J Drutz; W E Magee
Journal:  Am Rev Respir Dis       Date:  1982-05

8.  Candidiasis in cancer patients.

Authors:  G P Bodey
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

9.  Enhanced activity of streptomycin and chloramphenicol against intracellular Escherichia coli in the J774 macrophage cell line mediated by liposome delivery.

Authors:  M Stevenson; A J Baillie; R M Richards
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

10.  Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis.

Authors:  L E Adinolfi; P F Bonventre; M Vander Pas; D A Eppstein
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

View more
  13 in total

Review 1.  Activity of antibiotics against microorganisms ingested by mononuclear phagocytes.

Authors:  P J van den Broek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

2.  Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection.

Authors:  P M Melissen; W van Vianen; Y Rijsbergen; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

3.  Differences in virulence and in expression of PrfA and PrfA-regulated virulence genes of Listeria monocytogenes strains belonging to serogroup 4.

Authors:  Z Sokolovic; S Schüller; J Bohne; A Baur; U Rdest; C Dickneite; T Nichterlein; W Goebel
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.

Authors:  Jie He; Kamilia Abdelraouf; Kimberly R Ledesma; Diana S-L Chow; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2013-08-22       Impact factor: 5.283

Review 5.  Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections.

Authors:  I A Bakker-Woudenberg; A F Lokerse; M T ten Kate; P M Melissen; W van Vianen; E W van Etten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

Review 6.  Lipid formulations of amphotericin B. Less toxicity but at what economic cost?

Authors:  J Tollemar; O Ringdén
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

7.  The virulence gene cluster of Listeria monocytogenes is also present in Listeria ivanovii, an animal pathogen, and Listeria seeligeri, a nonpathogenic species.

Authors:  E Gouin; J Mengaud; P Cossart
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Determination of virulence of different strains of Listeria monocytogenes and Listeria innocua by oral inoculation of pregnant mice.

Authors:  A M Lammerding; K A Glass; A Gendron-Fitzpatrick; M P Doyle
Journal:  Appl Environ Microbiol       Date:  1992-12       Impact factor: 4.792

Review 9.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

10.  Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen.

Authors:  J M Boggs; N H Chang; A Goundalkar
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.